An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Booz Allen Wins a Position on BITSDIS – a $350M Biomedical Informatics & IT Support Contract for the National Cancer Institute
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary
Booz Allen Hamilton (NYSE: BAH) has secured a five-year IDIQ contract valued at up to $350 million from the National Institutes of Health’s National Cancer Institute. The initial task order is $29.9 million aimed at enhancing clinical trial reporting and facilitating data capture in cancer research. Booz Allen's role includes software development and operational support to ensure accurate information on cancer-related clinical trials and assist in the rapid deployment of COVID-19 vaccines.
Positive
$350 million IDIQ contract won from NIH's National Cancer Institute.
Initial task order valued at $29.9 million.
Negative
None.
MCLEAN, Va.--(BUSINESS WIRE)--
Booz Allen Hamilton (NYSE: BAH) announced today it won a position on Biomedical Information Technology, Software Development, and Informatics Support (BITSDIS), a five-year Indefinite-Delivery Indefinite-Quantity (IDIQ) contract worth up to $350 million to support the National Institutes of Health (NIH) National Cancer Institute (NCI) Center for Biomedical Informatics and Information Technology (CBIIT). As a part of this IDIQ, Booz Allen was awarded a $29.9 million task order to support the evolving needs of the cancer research community. Through this award, the Institute has selected a strategic partner that brings a cross-functional, integrated team that will bridge rapid advances between life science research, data science, and technology to drive scientific breakthroughs, support the clinical research enterprise, and strengthen its mission-critical operations.
Under the Clinical Trials Reporting Program (CTRP) task order, Booz Allen will provide the complete range of software development, system engineering, and operational support toward the following ends:
Enhance CTRP as the definitive source for information on all NCI-supported cancer-related clinical trials
Facilitate the capture of information across the cancer research ecosystem to improve clinical trial search, prioritization, and patient/trial matching
Support scientific research aimed to rapidly develop and deploy safe and effective COVID-19 vaccines through the collection, analysis, and reporting of serology test results
As an IDIQ awardee, Booz Allen will provide a broad range of biomedical information technology (IT), informatics, analytical, and consultative services to empower NCI’s clinicians and scientists with leading-edge capabilities and platforms to accelerate their research and support the Institute’s strategic programs and initiatives.
“As a long-standing partner of the National Institutes of Health, we are excited to bring our firm’s full suite of life science, cloud computing, advanced analytics, and technology modernization capabilities to accelerate cancer research and care,” said Roman Salasznyk, senior vice president and leader of Booz Allen’s life science practice. “We look forward to working with the National Cancer Institute to transform the cancer research enterprise by leveraging our deep scientific and technical talent base to meet the Institute’s informatics, data, and IT needs.”
About Booz Allen Hamilton For more than 100 years, military, government, and business leaders have turned to Booz Allen Hamilton to solve their most complex problems. As a consulting firm with experts in analytics, digital solutions, engineering, and cyber, we help organizations transform. We are a key partner on some of the most innovative programs for governments worldwide and trusted by its most sensitive agencies. We work shoulder-to-shoulder with clients, using a mission-first approach to choose the right strategy and technology to help them realize their vision.
With global headquarters in McLean, Virginia, our firm employs approximately 28,600 people globally as of June 30, 2021, and had revenue of $7.9 billion for the 12 months ended March 31, 2021. To learn more, visit www.boozallen.com. (NYSE: BAH)
What contract did Booz Allen Hamilton win from NIH?
Booz Allen Hamilton won a five-year IDIQ contract worth up to $350 million from the National Institutes of Health.
How much is the initial task order for Booz Allen Hamilton?
The initial task order for Booz Allen Hamilton is valued at $29.9 million.
What is the focus of Booz Allen Hamilton's contract with NCI?
The focus of the contract is on software development and operational support for enhancing clinical trial reporting and data capture in cancer research.
What are Booz Allen Hamilton's goals under the NIH contract?
Booz Allen aims to improve clinical trial search, prioritization, and patient/trial matching, while also supporting COVID-19 vaccine research.
What services will Booz Allen Hamilton provide to the National Cancer Institute?
Booz Allen Hamilton will provide biomedical information technology, informatics, analytical, and consultative services to the National Cancer Institute.
